Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients

• Main Authors: Yakov Lomakin, Alexey Belogurov, Irina Glagoleva, Alexey Stepanov, Konstantin Zakharov, John Okunola, Ivan Smirnov, Dmitry Genkin, Alexander Gabibov
• Format: Article
• Language: English
• Published: Hindawi Limited 2016-01-01
• Series: Mediators of Inflammation
• Online Access: http://dx.doi.org/10.1155/2016/2847232
• ISSN: 0962-9351; 1466-1861

We have previously shown that immunodominant MBP peptides encapsulated in mannosylated liposomes (Xemys) effectively suppressed experimental allergic encephalomyelitis (EAE). Within the frames of the successfully completed phase I clinical trial, we investigated changes in the serum cytokine profile after Xemys administration in MS patients. We observed a statistically significant decrease of MCP-1/CCL2, MIP-1β/CCL4, IL-7, and IL-2 at the time of study completion. In contrast, the serum levels of TNF-α were remarkably elevated. Our data suggest that the administration of Xemys leads to a normalization of cytokine status in MS patients to values commonly reported for healthy subjects. These data are an important contribution for the upcoming Xemys clinical trials.